Johnson & Johnson (JNJ) Tops Q4 EPS by 2c, Offers FY Guidance

Johnson & Johnson (NYSE: JNJ) reported Q4 EPS of $1.97, $0.02 better than the analyst estimate of $1.95. Revenue for the quarter came in at $20.4 billion versus the consensus estimate of $20.17 billion.

GUIDANCE:

Johnson & Johnson sees FY2019 EPS of $8.50-$8.65, versus the consensus of $8.61. Johnson & Johnson sees FY2019 revenue of $80.4-81.2 billion, versus the consensus of $82.68 billion.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
• General Mills (GIS) Tops Q1 EPS by 3c